Summary
Cytori Therapeutics Inc (Cytori) is a clinical stage regenerative medicine company. It develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) for the treatment of cardiovascular disease, orthopedic conditions and gastrointestinal disorders. The company has two therapeutic development platforms namely, Cytori Cell Therapy (CCT) and Cytori Nanomedicine. Cytori uses CCT platform based on the scientific discovery to develop variety of therapies with focus on the treatment of impaired hand function in scleroderma. The Cytori Nanomedicine is a versatile and novel protein-stabilized liposomal nanoparticle technology used for drug encapsulation. The company offers its products to the physicians, researchers, hospitals, clinics and other customers for commercial and research purposes. Cytori is headquartered in San Diego, California, the US.
Cytori Therapeutics Inc (CYTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Cytori Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Cytori Therapeutics Acquires Proprietary Nanoparticle Development Platform from Azaya Therapeutics 13
Partnerships 14
Cytori Therapeutics Enters into Distribution Agreement with Worthington Biochemical 14
Cytori Therapeutics Amends its Agreement with Biomedical Advanced Research and Development Authority 15
Licensing Agreements 16
Cytori Therapeutics Enters Into Licensing Agreement With Lorem Vascular 16
Cytori Therapeutics Enters Into Licensing Agreement With Bimini Technologies For Celution 17
Medistem Enters Into Licensing Agreement With Cytori Therapeutics 18
Equity Offering 18
Cytori Therapeutics Prices Public Offering of Shares for USD9.5 Million 18
Cytori Therapeutics Plans to Raise Funds through Public Offering of Shares 20
Cytori Therapeutics to Raise up to USD20 Million in Private Placement of Shares 21
Cytori Therapeutics Raises USD17 Million in Rights Offering of Units 22
Cytori Therapeutics Raises USD2.4 Million in Second Tranche of Private Placement of Units 23
Cytori Therapeutics Prices Private Placement of Units for USD25 Million 24
Cytori Therapeutics Raises USD13.5 Million in Private Placement of Units 26
Cytori Therapeutics Raises USD10 Million in Private Placement of Units 27
Cytori Therapeutics Completes Public Offering Of Shares For US$23 Million 28
Cytori Therapeutics Completes Private Placement Of Shares For US$18.2 Million 29
Asset Transactions 31
Bimini Technologies Acquires Puregraft Rights From Cytori Therapeutics For Up To US$15 Million 31
Cytori Therapeutics Inc - Key Competitors 33
Key Employees 34
Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
May 11, 2017: Cytori Reports First Quarter 2017 Business and Financial Results 36
Mar 23, 2017: Cytori Reports Fourth Quarter and Full Year 2016 Business and Financial Results 37
Nov 09, 2016: Cytori Reports Third Quarter 2016 Business and Financial Results 38
Aug 04, 2016: Cytori Reports Second Quarter 2016 Business and Financial Results 39
May 10, 2016: Cytori Reports First Quarter 2016 Business and Financial Results 41
Mar 03, 2016: Cytori Reports Fourth Quarter and Full Year 2015 Business and Financial Results 42
Corporate Communications 43
Apr 03, 2017: Cytori Appoints Gregg Lapointe to Board of Directors 43
Dec 28, 2016: Ronald Martell to Join Cytori Therapeutics’ Board of Directors 44
Legal and Regulatory 45
Feb 06, 2017: Cytori Receives U.S. Small Business Designation - Substantially Reduces 2017 FDA Filing Fees 45
May 10, 2016: Cytori Granted Broad European Orphan Drug Designation 46
Mar 23, 2016: Cytori Granted SME Status by European Medicines Agency 47
Government and Public Interest 48
Nov 14, 2016: Cytori Granted FDA Orphan Drug Designation for ECCS-50 in Scleroderma 48
Product News 49
Dec 14, 2016: Cytori Pivotal ADRESU Incontinence Trial Hits 50% Enrollment Milestone 49
Dec 05, 2016: Sustained Clinical Benefit After 3 Year Follow Up in Scleroderma Trial 50
Sep 26, 2016: Cytori Partner Kerastem Completes Enrollment of US Phase II Trial for Early Stage Hair Loss 51
Jul 19, 2016: Cytori Cell Therapy Phase I Trial Reports Maxillofacial Bone Regeneration 52
Jun 07, 2016: Cytori Announces Enrollment Completion in U.S. Phase III Scleroderma Trial 53
May 25, 2016: Cytori Fully Enrolls Pivotal U.S. Phase III Scleroderma Trial 54
May 24, 2016: Cytori Update on Its U.S. Phase III Scleroderma Trial 55
Feb 22, 2016: Data Reports Sustained Benefit at Two Years with Single Administration Cytori Cell Therapy for Scleroderma 56
Feb 08, 2016: Cytori Reports Interim Data on U.S. Phase II Osteoarthritis Trial 57
Feb 03, 2016: Cytori Cell Therapy Safe and Potentially Effective in EU Phase I Erectile Dysfunction Trial 58
Jan 19, 2016: Enrollment Begun on Phase II Clinical Trial in Crohn’s Disease 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60
List of Tables
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cytori Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Cytori Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cytori Therapeutics Acquires Proprietary Nanoparticle Development Platform from Azaya Therapeutics 13
Cytori Therapeutics Enters into Distribution Agreement with Worthington Biochemical 14
Cytori Therapeutics Amends its Agreement with Biomedical Advanced Research and Development Authority 15
Cytori Therapeutics Enters Into Licensing Agreement With Lorem Vascular 16
Cytori Therapeutics Enters Into Licensing Agreement With Bimini Technologies For Celution 17
Medistem Enters Into Licensing Agreement With Cytori Therapeutics 18
Cytori Therapeutics Prices Public Offering of Shares for USD9.5 Million 18
Cytori Therapeutics Plans to Raise Funds through Public Offering of Shares 20
Cytori Therapeutics to Raise up to USD20 Million in Private Placement of Shares 21
Cytori Therapeutics Raises USD17 Million in Rights Offering of Units 22
Cytori Therapeutics Raises USD2.4 Million in Second Tranche of Private Placement of Units 23
Cytori Therapeutics Prices Private Placement of Units for USD25 Million 24
Cytori Therapeutics Raises USD13.5 Million in Private Placement of Units 26
Cytori Therapeutics Raises USD10 Million in Private Placement of Units 27
Cytori Therapeutics Completes Public Offering Of Shares For US$23 Million 28
Cytori Therapeutics Completes Private Placement Of Shares For US$18.2 Million 29
Bimini Technologies Acquires Puregraft Rights From Cytori Therapeutics For Up To US$15 Million 31
Cytori Therapeutics Inc, Key Competitors 33
Cytori Therapeutics Inc, Key Employees 34
Cytori Therapeutics Inc, Other Locations 35
Cytori Therapeutics Inc, Subsidiaries 35List of Figures
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Cytori Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Cytori Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
